Home2018-11-19T18:16:54+00:00

Cognitive and Movement
Disorders Affect Millions

We are rapidly advancing a pipeline of novel allosteric modulators of ion channels – taking a well-established pharmaceutical approach and stepping out into new territory. SK channels and NMDA receptors are ion channels that are critical for modulating the strength, timing, and integration of communication between and within neurons and neuronal networks in the central nervous system. But there are no approved drugs that are selective allosteric modulators of these ion channels.  Cadent’s first-of-its-kind approach has the potential to bring harmony back to neuronal rhythms, effectively “re-wiring” the brain to treat movement and cognitive disorders.

Learn More About Our Approach
Movement Disorders

Our Focus on
Movement Disorders

We are developing positive allosteric modulators (PAMs) of SK (small-conductance calcium-activated potassium) channels in the brain for the treatment of essential tremor (ET) and spinocerebellar ataxia (SCA).

Cognitive Disorders

Our Focus on
Cognitive Disorders

Our approach aims to positively modulate NMDAr, a key receptor of the most abundant neurotransmitter Glutamate, to reverse NMDAr hypofunction in people with schizophrenia and restore cognitive balance.

Learn More
Learn More
6K

6,000 PEOPLE AFFECTED BY
SPINOCEREBELLAR ATAXIA IN THE U.S.

10MM

10 MILLION PEOPLE AFFECTED BY
ESSENTIAL TREMOR IN THE U.S.

2.2MM

2.2 MILLION PEOPLE AFFECTED BY
SCHIZOPHRENIA IN THE U.S.

Our Approach

We begin with a clear purpose: identifying a serious disease with clear unmet need. We apply novel approaches to discover new therapies and design well-controlled and powered studies to demonstrate the potential value of our medicines.

Patient
Selection

Use of genetics, translational biomarkers and other measures to carefully select patients

Patient Selection

For each disease we aim to treat, our goal is to target specific patient subsets based on genetics or other factors to identify the patients who will benefit most from treatment. In SCA, we are targeting only patients with genetically driven disease and in schizophrenia we are hoping our work in endpoint validation will lead to the development of relevant patient sub-groups that are most likely to benefit from intervention.

Target Specificity

Selection of novel, high-impact targets that can be modulated with specificity

Target Specificity

SK channels and NMDA channels are critical molecular determinants of brain circuit function, but have not been targeted with allosteric modulators for the treatment of movement or cognitive disorders. Allosteric modulation of ion channels is a proven approach to develop selective and clinically-meaningful CNS medicines. We have applied a proven medicinal chemistry approach to discover and develop positive and negative allosteric modulators of these ion channels as potential first-in-class therapeutics.

Drug Design + Optimization

Design of novel compounds to maximize benefit and minimize adverse effects

Drug Design + Optimization

We leverage our team’s significant industry experience in medicinal chemistry, target selection, drug discovery and drug optimization to rigorously evaluate our programs. Our goal is to produce candidates likely to achieve optimal efficacy with minimal side effects.

Quantitative Endpoints

Deploying novel insights to improve the precision of clinical endpoints

Quantitative Endpoints

We are working with pharmaceutical consortia and instrument companies to validate new “quantitative” endpoints that more accurately diagnose and measure disease severity than the current observation-based rating scales used by physicians. We are doing this by leveraging the best-possible measurement systems available in all of our programs.

Our Investors

News

Cadent Therapeutics Secures $40 Million Series B Financing to Advance Pipeline of Novel Therapies for Movement and Cognitive Disorders

November 15th, 2018|

Cadent Therapeutics, a company focused on the development of breakthrough therapies to improve the lives of patients with movement and cognitive disorders, today announced that it has raised $40 million in a Series B financing. In addition, the company has appointed Bob (Ibrahim) Dagher, M.D., as Chief Medical Officer.

Cadent Therapeutics Initiates Phase 1 Study of Lead Compound CAD-1883

March 12th, 2018|

Cadent Therapeutics, a precision neuroscience company developing novel medicines to restore movement and cognitive function in patients with neurological and psychiatric disease, today announced the initiation of a Phase 1 clinical study for its lead product candidate CAD-1883. The compound is a selective first-in-class positive allosteric modulator of the small conductance calcium-activated potassium (SK) channel.

See All Cadent News

We are developing novel allosteric modulators of ion channels to improve neuronal firing regularity. This first-of-its-kind approach has the potential to restore neuronal control and benefit patients with movement and cognitive disorders.

Contact Us to Learn More

We are developing novel allosteric modulators of ion channels to improve neuronal firing regularity. This first-of-its-kind approach has the potential to restore neuronal control and benefit patients with movement and cognitive disorders.

Contact Us to Learn More

We are developing novel allosteric modulators of ion channels to improve neuronal firing regularity. This first-of-its-kind approach has the potential to restore neuronal control and benefit patients with movement and cognitive disorders.

Contact Us to Learn More